Abstract: Postpartum haemorrhage is one of the most common causes of maternal death worldwide. Recombinant activated factor Ⅶ（rFⅦa） has already been successfully used for the treatment of bleeding episodes in patients with hemophilia A or B with formation of inhibitiors to factor Ⅷ or factor Ⅸ after replacement therapy and in other partients with inhibition of thrombin generating. Recently， scholars have found that rFⅦa plays wider roles in treating haemorrhage in patients with trauma， major surgery and even intractable obstetric and gynaecological hemorrhage. This article reviews the progress in the use of rFⅦa in intractable postpartum haemorrhage.

Key words: Postpartum hemorrhage, Recombinant proteins, Thrombin, Therapy